Strategic

Partnerships

We help you find, assess (through both a commercial and ethical lens) and integrate the right business partners and vendors in line with your organisation goals, standards and culture.

When compared to other industries, strategic partnerships in Pharma seem more successful according to industry experts, with a 50 - 60% success rate, compared to just 20% - 30% in other areas. In Digital Health only about 13% of partnerships between start-ups and Healthcare organisations succeed. They mainly fail due to corporate bureaucracy, lack of strategy and unaligned expectations.

The higher the differences in culture and values and the more divergent the ways of doing business, the higher the chances of difficulties are across all types of partnerships. That is why before any type of important deal or alliance, an organisation should perform some commercial due diligence and undertake an in-depth strategic vendor and/or partner assessment - to assess fit from various perspectives and mitigate risks, ultimately ensuring vendors and partners become long term synergistic partners, not foes.

And innovation always thrives in strategic collaboration(s).

__________________________________________________________________________________________________

Featured Insights

Quo Vadis: Strategic partnerships in Healthcare – the ecosystem model versus the paradox of competition & collaboration

Commercial and Vendor Due Diligence

Partner Profiling and Selection

Strategic Partner Assessment

Partnership Strategy

Strategic Portfolio Analysis and Management

MEDTECH

HEALTHCARE

PHARMA

Market and Competitive Analysis

Market and Competitor Strategy

Big Pharma Portfolio Strategy isn't about big volume = growth anymore

Innovation

Strategy

Ethics and Responsible Innovation pay off in the long run - a Deloitte study found that 76% of healthcare consumers and patients are more likely to trust companies that are transparent about how they use data and make decisions; also ethical design and transparency in clinical trials and post-market surveillance can lead to quicker approvals and fewer recalls, saving money long term and building a good reputation.

In a market like Pharma where only about 10% of drug candidates in development successfully navigate through all phases of clinical trials and regulatory approval to reach the commercialisation phase (IQVIA, 2024), we work with businesses to help them create capacity for innovation, improve ethical decision making and improve the odds of long term sustainable success.

In MedTech a significant higher number of products in development make it to the market compared to Pharma, yet large innovation barriers remain, mostly regulatory and governance related, but also related to new disruptive technologies, cybersecurity, financial and commercial risks. We help businesses navigate all these through a series of innovation frameworks and workshops. 

____________________________________________________________________________________________________________________________

Featured Insights

Big Pharma Portfolio Strategy isn't about big volume = growth anymore

Product Innovation

Process and Technological Innovation

Business Model Innovation

Disruptive Innovation

MEDTECH

HEALTHCARE

PHARMA

AI for Good Summit Geneva 2025 included a vast display of innovative medical technologies

SDA Bocconi in conversation with European policy makers on access to innovative medical devices in the EU

Mobile and online videogames - between addictive trouble makers and therapeutic medical devices (SaMD)

Training and Workshops

Ethics and Regulatory Strategy

We help you tackle regulation, understand ethical issues and effectively build a comprehensive, forward-looking plan that outlines how your company will navigate the legal, procedural and commercial requirements to bring a product to market and maintain its compliance throughout its lifecycle.

The EU has completed a major overhaul of its pharmaceutical legislation aimed at modernising how medicines are developed, authorised, supervised and made available across the Union, with explicit aims to support innovation, improve patient access, and address public‑health priorities (e.g., antimicrobials, rare diseases). This is a package of a new Regulation and a new Directive that together replace the core rules in force for two decades.

On the MedTech front, ongoing implementation problems with the MDR and IVDR have created certification bottlenecks, high administrative costs, and uneven interpretation across Member States. These regulations are now being updated in 2026. With potential impacts for those firms who have already started the application process as well as those coming to it. Especially impacted will be firms with SaMD, which will have a dual compliance obligation under the EU AI Act. 

With challenges come also opportunities: apart from challenges, there are also many opportunities created constantly by evolving regulatory requirements and market trends, shaped by both EU initiatives and competitor and consumer/patient dynamics.

____________________________________________________________________________________________________________________________

Featured Insights

Fewer MedTech start-ups listing in the EU – will the newly revised MDR/IVDR rules shake things up?

MDR/IVDR Rules

Planning and Risk Assessment

Regulatory Intelligence

MEDTECH

HEALTHCARE

PHARMA

Neurorights: the new frontier of neuronal data protection and individual mental space

Enhancing patient voice: EMA keen on integrating patient experience data in drug R&D and reimbursement

ISO 13485 will continue to mandate quality for MedTech to 2030, but firms should not get too comfortable

Ethical Design

IP Strategy